Emergent Total Assets vs Current Deferred Revenue Analysis

EBS Stock

USD 6.04 0.13 2.11%

Emergent Biosolutions financial indicator trend analysis is much more than just examining Emergent Biosolutions latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Emergent Biosolutions is a good investment. Please check the relationship between Emergent Biosolutions Total Assets and its Current Deferred Revenue accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Emergent Biosolutions. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.

For more information on how to buy Emergent Stock please use our How to Invest in Emergent Biosolutions guide.

Total Assets vs Current Deferred Revenue

Total Assets vs Current Deferred Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Emergent Biosolutions Total Assets account and Current Deferred Revenue. At this time, the significance of the direction appears to have fragmental relationship.

The correlation between Emergent Biosolutions' Total Assets and Current Deferred Revenue is 0.53. Overlapping area represents the amount of variation of Total Assets that can explain the historical movement of Current Deferred Revenue in the same time period over historical financial statements of Emergent Biosolutions, assuming nothing else is changed. The correlation between historical values of Emergent Biosolutions' Total Assets and Current Deferred Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Assets of Emergent Biosolutions are associated (or correlated) with its Current Deferred Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Current Deferred Revenue has no effect on the direction of Total Assets i.e., Emergent Biosolutions' Total Assets and Current Deferred Revenue go up and down completely randomly.

Correlation Coefficient

0.53

Relationship Direction	Positive
Relationship Strength	Weak

View All Relationships

Total Assets

Total assets refers to the total amount of Emergent Biosolutions assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Emergent Biosolutions books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Current Deferred Revenue

Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.

Most indicators from Emergent Biosolutions' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Emergent Biosolutions current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Emergent Biosolutions. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.

For more information on how to buy Emergent Stock please use our How to Invest in Emergent Biosolutions guide.At this time, Emergent Biosolutions' Selling General Administrative is comparatively stable compared to the past year. Issuance Of Capital Stock is likely to gain to about 8.8 M in 2024, whereas Tax Provision is likely to drop slightly above 48.4 M in 2024.

	2021	2022	2023	2024 (projected)
Total Operating Expenses	640.9M	593.2M	682.2M	716.3M
Cost Of Revenue	757.5M	693.7M	797.8M	837.6M

Total Operating Expenses Cost Of Revenue

Emergent Biosolutions fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Good Will	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock
Total Assets		0.96	0.43	0.79	0.97	0.85	0.88	0.75	0.53	0.87	0.83	0.76	0.46	0.87	0.44	0.62	0.66	0.45	0.82	0.83	0.79	0.99	0.77	0.72	0.79	0.64
Short Long Term Debt Total	0.96		0.57	0.9	0.88	0.89	0.94	0.75	0.51	0.85	0.87	0.87	0.35	0.85	0.36	0.61	0.52	0.42	0.84	0.85	0.66	0.99	0.8	0.84	0.82	0.64
Other Current Liab	0.43	0.57		0.73	0.27	0.77	0.59	0.75	0.68	0.4	0.78	0.78	-0.49	0.4	0.4	0.66	-0.21	0.52	0.79	0.71	-0.16	0.53	0.81	0.61	0.74	0.67
Total Current Liabilities	0.79	0.9	0.73		0.68	0.88	0.82	0.76	0.44	0.81	0.81	0.96	0.12	0.81	0.13	0.46	0.21	0.21	0.82	0.84	0.38	0.84	0.82	0.97	0.71	0.51
Total Stockholder Equity	0.97	0.88	0.27	0.68		0.78	0.75	0.7	0.46	0.87	0.72	0.64	0.57	0.87	0.42	0.52	0.75	0.36	0.74	0.77	0.87	0.92	0.69	0.62	0.66	0.56
Property Plant And Equipment Net	0.85	0.89	0.77	0.88	0.78		0.82	0.95	0.72	0.78	0.95	0.91	-0.03	0.78	0.52	0.74	0.3	0.56	0.98	0.95	0.38	0.88	0.97	0.77	0.88	0.76
Net Debt	0.88	0.94	0.59	0.82	0.75	0.82		0.64	0.5	0.63	0.88	0.8	0.24	0.63	0.48	0.7	0.43	0.51	0.79	0.73	0.57	0.93	0.7	0.76	0.89	0.7
Retained Earnings	0.75	0.75	0.75	0.76	0.7	0.95	0.64		0.81	0.75	0.89	0.83	-0.14	0.75	0.53	0.72	0.19	0.61	0.95	0.94	0.25	0.76	0.98	0.62	0.8	0.74
Accounts Payable	0.53	0.51	0.68	0.44	0.46	0.72	0.5	0.81		0.4	0.79	0.6	-0.36	0.4	0.79	0.92	0.17	0.88	0.81	0.66	0.06	0.56	0.81	0.24	0.79	0.93
Cash	0.87	0.85	0.4	0.81	0.87	0.78	0.63	0.75	0.4		0.65	0.76	0.45	1.0	0.1	0.34	0.53	0.17	0.71	0.82	0.65	0.85	0.75	0.78	0.52	0.38
Non Current Assets Total	0.83	0.87	0.78	0.81	0.72	0.95	0.88	0.89	0.79	0.65		0.88	-0.09	0.65	0.65	0.87	0.26	0.72	0.97	0.86	0.35	0.88	0.93	0.68	0.98	0.86
Non Currrent Assets Other	0.76	0.87	0.78	0.96	0.64	0.91	0.8	0.83	0.6	0.76	0.88		-0.04	0.76	0.26	0.61	0.13	0.38	0.88	0.82	0.28	0.82	0.89	0.89	0.79	0.63
Other Assets	0.46	0.35	-0.49	0.12	0.57	-0.03	0.24	-0.14	-0.36	0.45	-0.09	-0.04		0.45	-0.22	-0.26	0.76	-0.33	-0.11	0.05	0.87	0.38	-0.17	0.22	-0.11	-0.2
Cash And Short Term Investments	0.87	0.85	0.4	0.81	0.87	0.78	0.63	0.75	0.4	1.0	0.65	0.76	0.45		0.1	0.34	0.53	0.17	0.71	0.82	0.65	0.85	0.75	0.78	0.52	0.38
Net Receivables	0.44	0.36	0.4	0.13	0.42	0.52	0.48	0.53	0.79	0.1	0.65	0.26	-0.22	0.1		0.88	0.32	0.91	0.61	0.41	0.2	0.45	0.54	-0.06	0.72	0.85
Good Will	0.62	0.61	0.66	0.46	0.52	0.74	0.7	0.72	0.92	0.34	0.87	0.61	-0.26	0.34	0.88		0.27	0.95	0.82	0.62	0.2	0.67	0.76	0.28	0.92	0.98
Common Stock Shares Outstanding	0.66	0.52	-0.21	0.21	0.75	0.3	0.43	0.19	0.17	0.53	0.26	0.13	0.76	0.53	0.32	0.27		0.19	0.27	0.31	0.88	0.58	0.2	0.21	0.25	0.32
Non Current Liabilities Total	0.45	0.42	0.52	0.21	0.36	0.56	0.51	0.61	0.88	0.17	0.72	0.38	-0.33	0.17	0.91	0.95	0.19		0.66	0.47	0.08	0.49	0.62	0.01	0.79	0.89
Inventory	0.82	0.84	0.79	0.82	0.74	0.98	0.79	0.95	0.81	0.71	0.97	0.88	-0.11	0.71	0.61	0.82	0.27	0.66		0.92	0.33	0.85	0.98	0.68	0.91	0.83
Other Current Assets	0.83	0.85	0.71	0.84	0.77	0.95	0.73	0.94	0.66	0.82	0.86	0.82	0.05	0.82	0.41	0.62	0.31	0.47	0.92		0.38	0.84	0.92	0.74	0.77	0.66
Other Stockholder Equity	0.79	0.66	-0.16	0.38	0.87	0.38	0.57	0.25	0.06	0.65	0.35	0.28	0.87	0.65	0.2	0.2	0.88	0.08	0.33	0.38		0.71	0.25	0.4	0.34	0.24
Total Liab	0.99	0.99	0.53	0.84	0.92	0.88	0.93	0.76	0.56	0.85	0.88	0.82	0.38	0.85	0.45	0.67	0.58	0.49	0.85	0.84	0.71		0.8	0.77	0.84	0.68
Total Current Assets	0.77	0.8	0.81	0.82	0.69	0.97	0.7	0.98	0.81	0.75	0.93	0.89	-0.17	0.75	0.54	0.76	0.2	0.62	0.98	0.92	0.25	0.8		0.67	0.84	0.76
Short Term Debt	0.72	0.84	0.61	0.97	0.62	0.77	0.76	0.62	0.24	0.78	0.68	0.89	0.22	0.78	-0.06	0.28	0.21	0.01	0.68	0.74	0.4	0.77	0.67		0.57	0.34
Intangible Assets	0.79	0.82	0.74	0.71	0.66	0.88	0.89	0.8	0.79	0.52	0.98	0.79	-0.11	0.52	0.72	0.92	0.25	0.79	0.91	0.77	0.34	0.84	0.84	0.57		0.89
Common Stock	0.64	0.64	0.67	0.51	0.56	0.76	0.7	0.74	0.93	0.38	0.86	0.63	-0.2	0.38	0.85	0.98	0.32	0.89	0.83	0.66	0.24	0.68	0.76	0.34	0.89

Click cells to compare fundamentals

Emergent Biosolutions Account Relationship Matchups

Emergent Biosolutions fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	2.3B	2.9B	3.0B	3.2B	3.6B	3.8B
Short Long Term Debt Total	811.3M	874.8M	841M	1.4B	1.6B	1.7B
Other Current Liab	6.7M	83.1M	72.9M	169.1M	142.7M	149.8M
Total Stockholder Equity	1.1B	1.4B	1.6B	1.4B	1.6B	1.7B
Net Debt	643.5M	253.5M	264.9M	763.2M	877.7M	921.6M
Cash	167.8M	621.3M	576.1M	642.6M	739.0M	775.9M
Other Assets	65.6M	115M	57.3M	191.3M	220.0M	231.0M
Cash And Short Term Investments	167.8M	621.3M	576.1M	642.6M	739.0M	775.9M
Common Stock Shares Outstanding	52.4M	53.8M	54.1M	50.1M	57.6M	41.4M
Liabilities And Stockholders Equity	2.3B	2.9B	3.0B	3.2B	3.6B	3.8B
Other Stockholder Equity	676.5M	745.3M	677.2M	645.8M	742.7M	779.8M
Total Liab	1.2B	1.4B	1.3B	1.8B	2.1B	2.2B
Other Liab	199.9M	210.7M	156.8M	90.4M	104.0M	66.7M
Current Deferred Revenue	101.9M	131.5M	140.4M	26.4M	30.4M	28.1M
Long Term Debt	798.4M	841M	809.4M	448.5M	446.5M	290.2M
Property Plant And Equipment Gross	542.3M	644.1M	800.1M	817.6M	794.2M	833.9M
Accumulated Other Comprehensive Income	(9.9M)	(25.3M)	(16.1M)	3.1M	2.8M	2.9M
Property Plant Equipment	542.3M	644.1M	800.1M	817.6M	940.2M	987.3M
Retained Earnings Total Equity	421.8M	726.9M	957.8M	734M	844.1M	440.2M
Deferred Long Term Liab	63.9M	53.2M	94.9M	71.8M	82.6M	86.7M

Pair Trading with Emergent Biosolutions

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Emergent Biosolutions position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Emergent Biosolutions will appreciate offsetting losses from the drop in the long position's value.

Moving together with Emergent Stock

0.68

ELUT

Elutia Inc Symbol Change

Pair Corr

Moving against Emergent Stock

0.93	LYRA	Lyra Therapeutics	Pair Corr
0.67	VRDN	Viridian Therapeutics Earnings Call This Week	Pair Corr
0.62	RGEN	Repligen	Pair Corr
0.55	ETNB	89bio Inc	Pair Corr
0.55	XFOR	X4 Pharmaceuticals	Pair Corr

The ability to find closely correlated positions to Emergent Biosolutions could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Emergent Biosolutions when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Emergent Biosolutions - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Emergent Biosolutions to buy it.

The correlation of Emergent Biosolutions is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Emergent Biosolutions moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Emergent Biosolutions moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Emergent Biosolutions can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for Emergent Stock Analysis

When running Emergent Biosolutions' price analysis, check to measure Emergent Biosolutions' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Emergent Biosolutions is operating at the current time. Most of Emergent Biosolutions' value examination focuses on studying past and present price action to predict the probability of Emergent Biosolutions' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Emergent Biosolutions' price. Additionally, you may evaluate how the addition of Emergent Biosolutions to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC